KRAS and familial pancreatic carcinoma: After the screening, KRAS gene mutation, hyperlipidaemia, pancreatitis, and pancreatic cysts were entered into the model as independent variables, and KRAS gene mutation (OR = 8.99, 95% CI: 5.48–15.46, p < 0.001), hyperlipidaemia (OR = 3.46, 95% CI: 1.45–7.65, p = 0.003), pancreatitis (OR = 25.30, 95% CI: 11.46–57.79 p < 0.001), and pancreatic cysts (OR = 21.12, 95% CI: 4.71–119.03, p = 0.0001) were significantly associated with the risk of developing pancreatic cancer (Supplementary Table S1).